Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance

Ginkgo Bioworks Holdings IncTrade
iShares Broad USD Investment Grade Corporate BondTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.51 (market cap $515.15M), while iShares Broad USD Investment Grade Corporate Bond trades at $50.21. The key difference: Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.

DNAUSIG
Market Cap
$515.15M
Sector
HealthFixed Income
52-Week High
$16.14$52.69
52-Week Low
$5.48$50.18
Enterprise Value
$617.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.

DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.

iShares Broad USD Investment Grade Corporate Bond

USIG trades at $50.40 with minimal daily movement (+0.16%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The company maintains consistent dividend distributions, with recent payouts of $0.20-$0.21 per share. Recent news includes AM Best affirming credit ratings for subsidiaries following a transaction with Tiptree Inc.

Investment outlook remains cautious given bearish technical signals and limited fundamental data availability. The steady dividend history provides income appeal, but investors face uncertainty from incomplete financial metrics. Key risks include potential volatility from institutional positioning changes and transaction integration challenges with Tiptree.

Returns comparison

Trailing returns across standard periods

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About iShares Broad USD Investment Grade Corporate Bond

USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.

Read more on USIG